Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > S&P Biotech about 1% from 52- week high

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Feb 15, 2024 4:22pm

69 Views

Post# 35882770

RE:Re: S&P Biotech about 1% from 52- week high

This is a unique moment when so much is known behind closed doors. Ronnie Miller is "thrilled" with Gilles in the catbird seat of both companies. What do they know? They want CZO on NASDAQ. Why? Ronnie Miller is "thrilled". Let that sink in. A deal on AEZS's diagnostic is expected and Gilles should have a very good idea about the terms. CZO has also had discussions with serious potential partners concerning PGX as of the AGM as PGX is expected to be scaled up to the point of decision concerning mass industrialization in Q3 with industry leader Natex. We've never seen data for CZO's avenanthramide pill and soon we could get human data. It wouldn't surprise me if the single ascending dose portion of the trial is completed this month. From no data to human data? More data will be needed however. Gilles also called the wound healing data a 'home run' and it will soon be up for partnering. AEZS also appears near a go decision for one or more pipeline programs. H.C. Wainwright has a US$15 target price for AEZS. What is the program for significant growth that AEZS's capital is expected to fuel? The plan is currently behind closed doors. We haven't seen the plan. This situation is a mystery in an off-the-radar company with a retail shareholder base. So much is known inside.